

Amgen Inc IMDELLTRA All References

1. [Siegel RL, et al.](#) Cancer statistics, 2022. *CA Cancer J Clin.* 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2. [Sabari JK, et al.](#) Unravelling the biology of SCLC: implications for therapy. *Nat Rev Clin Oncol.* 2017;14:549-56.
3. [SEER*Explorer: An interactive website for SEER cancer statistics.](#) Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2025 Apr 14].
4. [Slotman B, et al.](#) Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med.* 2007;357:664-672.
5. [Takahashi T, et al.](#) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2017;18(5):663-671.
6. [Paz-Ares L, et al.](#) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet.* 2019;394:1929-1939.
7. [Horn L, et al.](#) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med.* 2018;379:2220-2229.
8. [von Pawel J, et al.](#) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol.* 1999;17:658-667.
9. [von Pawel J, et al.](#) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J Clin Oncol.* 2014;32:4012-4019.
10. [Farago AF, et al.](#) ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. *Future Oncol.* 2019;15:231-239.
11. [Trigo J, et al.](#) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol.* 2020;21:645-654.

12. [Onoda S, et al.](#) Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. *J Clin Oncol.* 2006;24:5448-5453.
13. [Horita N, et al.](#) Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. *Sci Rep.* 2015;5:15437.
14. [Owen DH, et al.](#) DLL3: an emerging target in small cell lung cancer. *J Hematol Oncol.* 2019;12(1):61.
15. [Paz-Ares L, et al.](#) Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. *J Clin Oncol.* 2023;41(16):2893-2903.
16. [Ahn MJ, et al.](#) Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. *N Engl J Med.* 2023;389(22): 2063-2075.
17. [Giffin MJ, et al.](#) AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. *Clin Cancer Res.* 2021;27(5):1526-1537.
18. [Sands J, et al.](#) Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up. *Journal of Thoracic Oncology.* OA10.03. 2024;19(10):S30 - S31.
19. [Ready N, et al.](#) Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. *J Thorac Oncol.* 2019;14: 237-44.
20. [Chung HC, et al.](#) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thorac Oncol.* 2020;15: 618-27.
21. [FDA Approval Announcement](#): U.S. Food and Drug Administration (FDA) website --- IMDELLTRA® (tarlatamab) approval, May 16, 2024.
22. [Einsele H, et al.](#) The BiTE® (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. *Cancer.* 2020;126(14):3192-3201.
23. [Wolf E, et al.](#) BiTEs®: bispecific antibody constructs with unique anti-tumor activity, *Drug Discov Today.* 2005;10(18):1237-1244.
24. [Tendler S, et al.](#) Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer? *J Clin Oncol.* 2023;41(16):2877-2880.

